{"nctId":"NCT03320018","briefTitle":"Neuroprotection in Acute Ischemic Stroke","startDateStruct":{"date":"2017-08-02","type":"ACTUAL"},"conditions":["Stroke, Ischemic"],"count":15,"armGroups":[{"label":"Hydrogen/Minocycline","type":"EXPERIMENTAL","interventionNames":["Drug: Hydrogen","Drug: Minocycline"]},{"label":"Placebo Hydrogen/Placebo Minocycline","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Hydrogen","Other: Placebo Minocycline"]}],"interventions":[{"name":"Hydrogen","otherNames":["H2"]},{"name":"Minocycline","otherNames":["Minocin","Minomycin","Akamin"]},{"name":"Placebo Hydrogen","otherNames":[]},{"name":"Placebo Minocycline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 18 years old or over\n2. Presenting to/at Stony Brook University Hospital with acute ischemic stroke\n3. Baseline (at admission to study) National Institute of Health Stroke Scale (NIHSS) of â‰¥ 5\n4. Administration of study medication possible within 24 hours of last known well\n\nExclusion Criteria:\n\n1\\. Pre-existing neurological disability (historical NIHSS \\> 3); unable to live independently 3. Severe stroke or comorbidities likely to result in patient dying within 3 months 4. Acute or chronic renal failure with calculated creatinine clearance \\< 30 5. Liver disease leading to \\> 3x elevation in liver transaminases or significant loss of synthetic capacity\\* 6. Thrombocytopenia (\\<100x10\\^9platelets / L blood) 7. Pre-existing infectious disease requiring antibiotic therapy that have a negative interaction with minocycline. (Penicillin, amoxicillin, ampicillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, methicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin) 8. Pregnancy or nursing. Females of reproductive age will be required to use barrier contraception or abstain from sexual intercourse while on study medications, as minocycline may render oral contraceptives less effective.\n\n9\\. Known allergy to tetracycline group of drugs 10. Concurrent treatment with retinoids or ergot alkaloids 11. Inability to safely tolerate the fluid load (iv normal saline or po water) associated with study medication\\* 12. Treatment with another investigational drug within the last 30 days that may interfere with this study's medications\\* 13. Inability to tolerate or comply with study procedures\\*","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Favorable Outcome on the Simplified Modified Rankin Scale (sMRSq)","description":"rating scale to assess level of functional independence for patients post-stroke. Scores range from 0 (no symptoms) to 6 (dead).\n\nmRS scores at 90 days will be classified as favorable or unfavorable based on the baseline NIHSS measured at time of enrollment. Subjects in the lowest baseline severity tertile (NIHSS 5-7) will need to have a 90 day mRS score of 0 to be considered to have a favorable outcome. Subjects with baseline NIHSS 8-14 will need a 90 day mRS score 0-1 to be considered to have a favorable outcome; those with baseline NIHSS 15-25 will need a 90 day mRS score 0-2 to be considered to have a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Simplified Modified Rankin Scale (sMRSq)","description":"rating scale to assess level of functional independence for patients post-stroke. Scores range from 0 (no symptoms) to 6 (dead).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.6"},{"groupId":"OG001","value":"3.4","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"NIH Stroke Scale (NIHSS)","description":"15-item neurologic examination scale for severity of stroke. Ratings for each item are scored with 3 to 5 grades. A total NIHSS of 0 is normal; 1-4 is considered a minor stroke; 5-15 moderate; 16-20 moderate to severe; and 21-42 severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"4.2"},{"groupId":"OG001","value":"7.5","spread":"3.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":6},"commonTop":["rash","hypotension","headache","Hypotension","urinary tract infection"]}}}